Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
$5.35
+8.1%
$5.30
$1.67
$7.29
$524.23M0.944.96 million shs6.03 million shs
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
$14.33
+1.3%
$12.51
$4.81
$27.50
$481.40MN/A328,877 shs280,074 shs
Scilex Holding Company stock logo
SCLX
Scilex
$18.87
+10.1%
$10.61
$3.60
$45.15
$119.22M1.32313,464 shs465,891 shs
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
$5.93
+4.8%
$5.74
$2.41
$10.07
$440.74M2.441.16 million shs794,407 shs
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
+8.08%+9.18%-19.06%+42.67%+184.57%
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
+1.27%-2.65%+4.75%+17.94%+1,432,999,900.00%
Scilex Holding Company stock logo
SCLX
Scilex
+10.09%+4.37%+66.11%+314.73%-56.52%
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
+4.77%-2.95%-12.28%+111.03%-40.40%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
2.5237 of 5 stars
3.61.00.00.03.31.70.6
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
1.9636 of 5 stars
3.50.00.00.01.11.70.6
Scilex Holding Company stock logo
SCLX
Scilex
2.4471 of 5 stars
3.32.00.00.03.11.70.6
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
3.266 of 5 stars
4.62.00.00.02.11.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
3.17
Buy$23.25334.58% Upside
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
3.00
Buy$37.63162.56% Upside
Scilex Holding Company stock logo
SCLX
Scilex
2.50
Moderate Buy$455.002,311.23% Upside
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
3.17
Buy$15.00152.95% Upside

Current Analyst Ratings Breakdown

Latest SCLX, MBX, ATYR, and SLDB Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/22/2025
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$9.00 ➝ $17.00
8/14/2025
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$15.00
8/14/2025
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$15.00 ➝ $13.00
8/13/2025
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$17.00 ➝ $14.00
8/5/2025
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$38.00
7/21/2025
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetOverweight ➝ Overweight$16.00
7/16/2025
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$38.00
6/26/2025
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$14.00
6/26/2025
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$14.00
6/20/2025
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$17.00 ➝ $25.00
6/17/2025
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$20.00
(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
N/AN/AN/AN/A$0.76 per shareN/A
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
N/AN/AN/AN/AN/AN/A
Scilex Holding Company stock logo
SCLX
Scilex
$56.59M2.32N/AN/A($35.80) per share-0.53
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
$8.09M57.08N/AN/A$3.32 per share1.79
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
-$64.02M-$0.80N/AN/AN/AN/A-93.69%-68.83%11/6/2025 (Estimated)
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
N/A-$4.54N/AN/AN/AN/AN/AN/AN/A
Scilex Holding Company stock logo
SCLX
Scilex
-$72.81M-$29.02N/AN/AN/A-179.12%N/A-109.95%N/A
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
-$124.70M-$2.80N/AN/AN/AN/A-69.70%-56.74%11/5/2025 (Estimated)

Latest SCLX, MBX, ATYR, and SLDB Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2025Q2 2025
Scilex Holding Company stock logo
SCLX
Scilex
-$4.55-$7.42-$2.87-$7.42$26.25 million$9.90 million
8/12/2025Q2 2025
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
-$0.51-$0.42+$0.09-$0.42N/AN/A
8/7/2025Q2 2025
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
-$0.18-$0.22-$0.04-$0.22N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
N/AN/AN/AN/AN/A
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
N/AN/AN/AN/AN/A
Scilex Holding Company stock logo
SCLX
Scilex
N/AN/AN/AN/AN/A
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
0.01
5.63
5.63
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
N/AN/AN/A
Scilex Holding Company stock logo
SCLX
Scilex
N/A
0.11
0.10
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
N/A
9.34
9.34

Institutional Ownership

CompanyInstitutional Ownership
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
61.72%
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
N/A
Scilex Holding Company stock logo
SCLX
Scilex
69.67%
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
81.46%

Insider Ownership

CompanyInsider Ownership
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
3.70%
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
52.19%
Scilex Holding Company stock logo
SCLX
Scilex
7.94%
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
1.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
5397.99 million94.36 millionOptionable
MBX Biosciences, Inc. stock logo
MBX
MBX Biosciences
3633.59 millionN/AN/A
Scilex Holding Company stock logo
SCLX
Scilex
806.96 million6.40 millionOptionable
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
10077.87 million76.39 millionOptionable

Recent News About These Companies

Q3 EPS Forecast for Solid Biosciences Increased by Analyst
Leerink Partnrs Weighs in on SLDB Q1 Earnings
HC Wainwright Brokers Reduce Earnings Estimates for SLDB

New MarketBeat Followers Over Time

Media Sentiment Over Time

aTyr Pharma stock logo

aTyr Pharma NASDAQ:ATYR

$5.35 +0.40 (+8.08%)
Closing price 08/22/2025 04:00 PM Eastern
Extended Trading
$5.38 +0.03 (+0.47%)
As of 08/22/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

MBX Biosciences stock logo

MBX Biosciences NYSE:MBX

$14.33 +0.18 (+1.27%)
Closing price 08/22/2025 04:00 PM Eastern
Extended Trading
$14.34 +0.01 (+0.03%)
As of 08/22/2025 06:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies designed as a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug for treating obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.

Scilex stock logo

Scilex NASDAQ:SCLX

$18.87 +1.73 (+10.09%)
Closing price 08/22/2025 04:00 PM Eastern
Extended Trading
$18.93 +0.06 (+0.34%)
As of 08/22/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company is also developing three product candidates, including SP-102 (10 mg dexamethasone sodium phosphate viscous gel) (SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a Phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4% (SP-103), a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a Phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules) (SP-104), a novel low-dose delayed-release naltrexone hydrochloride, which has completed Phase 1 trials for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California.

Solid Biosciences stock logo

Solid Biosciences NASDAQ:SLDB

$5.93 +0.27 (+4.77%)
Closing price 08/22/2025 04:00 PM Eastern
Extended Trading
$5.90 -0.03 (-0.57%)
As of 08/22/2025 05:13 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Solid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia. It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which helps coordinate contraction of the heart muscle; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, a cardiac splicing factor that regulates alternative splicing, and codes for RNA binding motif protein 20; and AVB-202-TT to treat Friedreich's ataxia, as well as other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne; and a license agreement with the University of Washington, University of Missouri, and University of Florida. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.